Annual Report

Overview

The report describes 2019 as the first year of commercial sales for Toripalimab, with total revenue of RMB775.1 million. Its ESG appendix reports Scope 1 and Scope 2 emissions and total energy and water consumption within the stated environmental reporting boundary. The group reported 1,421 employees and no work-related fatalities during the year.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2019
Period: 1 January 2019 – 31 December 2019
Publication date: 27 March 2020
Language: English
Pages
File size
Restatement: Disclosed

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services